Marshall Wace
CRVS icon

Marshall Wace’s Corvus Pharmaceuticals CRVS Stock Holding History

Marshall Wace’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Sell
100,474
-447,811
-82% -$6.21M ﹤0.01% 2004
2026
Q1 		$8.02M Buy
548,285
+332,037
+154% +$5.3M 0.01% 1078
2025
Q4 		$1.67M Buy
+216,248
New +$1.71M ﹤0.01% 1665
2025
Q3 		– Sell
-201,651
Closed -$807K – 2964
2025
Q2 		$807K Buy
201,651
+46,880
+30% +$171K ﹤0.01% 1941
2025
Q1 		$492K Buy
+154,771
New +$729K ﹤0.01% 2084
2024
Q4 		– Sell
-323,211
Closed -$1.71M – 2642
2024
Q3 		$1.71M Buy
323,211
+248,652
+333% +$893K ﹤0.01% 1430
2024
Q2 		$136K Buy
+74,559
New +$139K ﹤0.01% 2367
2023
Q4 		– Sell
-198,220
Closed -$289K – 2235
2023
Q3 		$289K Sell
198,220
-100,920
-34% -$213K ﹤0.01% 1896
2023
Q2 		$685K Buy
+299,140
New +$621K ﹤0.01% 1870

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Marshall Wace's CRVS Position: Q2 2026 in Review

Marshall Wace reduced its Corvus Pharmaceuticals (CRVS) stake by 82% in Q2 2026, selling an estimated $6.21M and leaving 100,474 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

Marshall Wace first reported a position in CRVS in Q2 2023 and has held it in 9 quarters since. The position peaked at $8.02M in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Marshall Wace held 100,474 shares of Corvus Pharmaceuticals worth $1.5M as of Q2 2026.
  • Marshall Wace sold 447,811 Corvus Pharmaceuticals shares in Q2 2026, an estimated $6.21M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2004 holding.
  • Marshall Wace first reported a position in Corvus Pharmaceuticals in Q2 2023 and has held it in 9 quarters since.
  • Marshall Wace's Corvus Pharmaceuticals position peaked at $8.02M in Q1 2026.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.